Voxel-based comparison of regional cerebral glucose metabolism between PSP and corticobasal degeneration
Introduction
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neurodegenerative disorders of middle and late age presenting with dementia and parkinsonism. The neurological features of PSP included impaired ocular motility, pseudobulbar palsy, and axial dystonia, while those of CBD include asymmetric rigidity of the limbs, myoclonus, alien limb sign, and localized cortical signs such as apraxia or cortical sensory loss. The clinical syndromes of typical cases of PSP and CBD are distinct, although atypical cases are described that have overlapping clinical and pathologic features. Several pathologic features, such as astrocytic lesions and ballooned neurons, differentiate PSP from CBD, although both diseases share several neuropathological features including filamentous tau inclusions in neurons and glia and biochemical alterations in the tau protein. Several clinical, pathological, and molecular features rationalize the concept of sporadic form of tauopathy. Nevertheless, there are sufficient differences to continue the present-day trend to consider PSP and CBD as separate disorders [1], [2].
These two diseases are sometimes difficult to distinguish on clinical grounds. Functional neuroimagings such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) may help to differentiate CBD from PSP. A number of studies with PET and SPECT have demonstrated cerebral metabolism or perfusion abnormalities in PSP and CBD, separately. CBD patients are characterized by an asymmetric hypometabolism mainly in the sensorimotor and parietal cortices and the thalamus, while PSP patients are characterized by a global metabolic reduction mainly in the frontal lobes and the basal ganglia. However, only a few studies have made direct comparisons of the two diseases [3], [4], [5], [6], and there are some discrepancies in the results of these studies. The disagreement among the studies may be due to the use of groups of patients that were not matched in terms of age, cognitive impairment, or hemisphere that was most affected. The purpose of the present study was to delineate the pathophysiological difference between PSP and CBD by using fluorodeoxyglucose (FDG)-PET. By a voxel-by-voxel analysis, we compared two groups equivalent for age, gender, cognitive impairment, and hemisphere that was most affected.
Section snippets
Subjects
A total of 12 patients with probable PSP diagnosed by NINDS-SPSP International Workshop [7] and 12 patients with probable CBD that fulfilled the criteria of the CBD Multicenter Case-Control Study (CBDMCCS) [8] were selected from patients who were admitted to our hospital for examination of cognitive impairment. The two groups were matched for age and scores on the Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale (ADAS). The PSP patients consisted of seven males and
Results
Asymmetry was positive in 10 of the 12 patients with CBD, and mirror PET images were made for 5 CBD patients with a right predominance. Of the 12 patients with PSP, 1 had a left predominance and, as a result, there was no need for preparing mirror images. None of the healthy controls had hemispheric asymmetry.
In the PSP group, cerebral glucose metabolism was significantly decreased in the anterior cingulate gyrus, inferior frontal gyrus, caudate nucleus, and midbrain compared with the control
Discussion
In patients with PSP, glucose metabolism was decreased in the lateral and medial frontal lobes, caudate nucleus, and midbrain as compared with age-matched healthy controls. These findings were consistent with those of previous ROI-based studies and a voxel-based study. In PSP, the basal ganglia and brain stem are the main loci of pathological changes, while the cortical regions have only a slight pathological involvement [22]. However, there seems to be agreement among previous functional
Conclusions
In PSP patients, the metabolic reduction is dominant in the frontal lobe, while in CBD patients, the metabolic reduction is dominant in the parietal lobe. These differences in glucose metabolism appear to reflect the pathological and clinical differences between these two diseases that are especially characterized by cognitive impairments. These findings suggest that measurement of glucose metabolism by PET followed by a voxel-based analysis is useful to understand pathophysiology of these two
References (26)
- et al.
Heterogeneity of glucose metabolism in corticobasal degeneration
J. Neurol. Sci.
(1998) Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration
J. Neurol.
(1999)- et al.
Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy
Ann. Neurol.
(2000) - et al.
Cerebral glucose metabolism in corticobasal degeneration: comparison with progressive supranuclear palsy and normal controls
Mov. Disord.
(1997) - et al.
Cerebral blood flow in corticobasal degeneration and progressive supranuclear palsy
Alzheimer Dis. Assoc. Disord.
(2000) - et al.
Voxel-based distribution of metabolic impairment in corticobasal degeneration
Mov. Disord.
(2000) - et al.
PET and the investigation of dementia in the parkinsonian patient
J. Neural Transm., Suppl.
(1997) - et al.
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome): report of the NINDS-SPSP international workshop
Neurology
(1996) - et al.
Cortical-basal ganglionic degeneration
- et al.
Accuracy of the clinical diagnosis of corticobasal degeneration
Neurology
(1997)